

## Best practices on pregnancy on dialysis: the Italian Study Group on Kidney and Pregnancy

Gianfranca Cabiddu<sup>1</sup> · Santina Castellino<sup>2</sup> · Giuseppe Gernone<sup>3</sup> · Domenico Santoro<sup>4</sup> · Franca Giacchino<sup>5</sup> · Olga Credendino<sup>6</sup> · Giuseppe Daidone<sup>7</sup> · Gina Gregorini<sup>8</sup> · Gabriella Moroni<sup>9</sup> · Rossella Attini<sup>10</sup> · Fosca Minelli<sup>10</sup> · Gianfranco Manisco<sup>11</sup> · Tullia Todros<sup>10</sup> · Giorgina Barbara Piccoli<sup>12</sup> · On behalf of Kidney and Pregnancy Study Group of Italian Society of Nephrology

Received: 29 December 2014 / Accepted: 6 March 2015 / Published online: 13 May 2015  
© Italian Society of Nephrology 2015

### Abstract

**Background** Pregnancy during dialysis is increasingly being reported and represents a debated point in Nephrology. The small number of cases available in the literature makes evidence-based counselling difficult, also given the cultural sensitivity of this issue. Hence, the need for position statements to highlight the state of the art and propose the unresolved issues for general discussion.

**Methods** A systematic analysis of the literature (MESH, Emtree and free terms on pregnancy and dialysis) was conducted and expert opinions examined (Study Group on Kidney and Pregnancy; experts involved in the management of pregnancy in dialysis in Italy 2000–2013).

Questions regarded: timing of dialysis start in pregnancy; mode of treatment, i.e. peritoneal dialysis (PD) versus haemodialysis (HD); treatment schedules (for both modes); obstetric surveillance; main support therapies (anaemia, calcium-phosphate parathormone; acidosis); counselling tips.

**Main results** Timing of dialysis start is not clear, considering also the different support therapies; successful pregnancy is possible in both PD and HD; high efficiency and strict integration with residual kidney function are pivotal in both treatments, the blood urea nitrogen test being perhaps a useful marker in this context. To date, long-hour HD has provided the best results. Strict, personalized obstetric surveillance is warranted; therapies should be aimed at avoiding vitamin B<sub>12</sub>, folate and iron deficits, and at correcting anaemia; vitamin D and calcium administration is safe and recommended. Women on dialysis should be advised that pregnancy is possible, albeit rare, with both types of dialysis treatment, and that a success rate of over 75 % may be achieved. High dialysis efficiency and frequent controls are needed to optimize outcomes.

**Keywords** Chronic kidney disease · Hemodialysis · Peritoneal dialysis · Dialysis efficiency · Evidence based medicine · Daily dialysis

✉ Giorgina Barbara Piccoli  
gbpiccoli@yahoo.it; giorgina.piccoli@unito.it

- <sup>1</sup> Nephrology, Azienda Ospedaliera Brotzu, Cagliari, Italy
- <sup>2</sup> Nephrology and Dialysis, Taormina Hospital, Taormina, Italy
- <sup>3</sup> Nephrology, S. Maria Degli Angeli Hospital, Putignano, Italy
- <sup>4</sup> Nephrology and Dialysis, AOU “G.Martino”, Messina, Italy
- <sup>5</sup> Nephrology, Ospedale d’Ivrea, Turin, Italy
- <sup>6</sup> Nephrology and Dialysis, Ospedale Cardarelli, Naples, Italy
- <sup>7</sup> Nephrology, Siracusa Hospital, Siracusa, Italy
- <sup>8</sup> Nephrology, Spedali Civili di Brescia, Brescia, Italy
- <sup>9</sup> Nephrology, Fondazione Ca’ Granda Ospedale Maggiore, Milan, Italy
- <sup>10</sup> Obstetrics, Department of Surgery, University of Torino, Turin, Italy
- <sup>11</sup> Nephrology, Camberlingo Hospital, Francavilla Fontana, Italy
- <sup>12</sup> Nephrology, SS Nephrology, ASOU san Luigi, Department of Clinical and Biological Sciences, University of Torino, Regione Gonzole 10, Orbassano Torino, Italy 10100

### Introduction

From the first reports in the early 1970s of successful pregnancy in dialysis up until the year 2000, pregnancy during dialysis was considered an exceptional occurrence, alternatively considered a miracle or an event to be discouraged due to both the maternal and the foetal risks [1–

4]. The scenario in the new millennium has changed somewhat for at least three main reasons.

Firstly, the diffusion of dialysis in countries where attitudes towards pregnancy and chronic diseases differ from western countries and where a strong cultural drive towards large families and less influence of “invisible” diseases such as end-stage renal disease (ESRD) on social life may be observed has made it possible to collect large series of dialysis patients undergoing successful pregnancies, thus leading to a more positive approach to pregnancy in dialysis [5–10]. Secondly, the impressive increase in dialysis efficiency provided by “intensive” non-conventional schedules (mainly long-hour nightly dialysis) has allowed us to achieve unprecedented results in pregnant women on dialysis, confronting the nephrological community with the need for a new standard of dialysis efficiency [11–13]. Thirdly, the growing trend towards empowering patients is changing the attitude regarding decisions that were once “contraindicated”, and may be one of the reasons for the increase in pregnancy in women on dialysis in the western world [14, 15].

The Italian Study Group on Kidney and Pregnancy has undertaken a nationwide survey on pregnancy in chronic dialysis and transplantation, allowing us to quantify the Italian experience in the new millennium [16]. The odds of having a child on dialysis are about 1:100 with respect to the Italian population of the same age group, and about 1:10 with respect to grafted women. These data are in agreement with results of the ANZDATA Registry which reported the results of a large survey carried out in Australia and New Zealand [17, 18]. Our study on pregnancy in on-dialysis women in Italy was an opportunity to increase awareness on this topic in our country and to set the stage for the present “best practice” review.

### **Evidence-based medicine and pregnancy in dialysis: methodological insights**

The evidence concerning pregnancy during dialysis is subject to certain methodological issues related to pregnancy per se and to rare events. The first issue regards randomized trials. Clearly, pregnancy itself cannot be randomized and, furthermore, randomization of any treatment in pregnancy is complex, and often ethically unfeasible. Therefore, no randomized controlled trials (RCTs) are foreseen to study dialysis duration, frequency or schedules in association with pregnancy or obstetric care policies.

The second issue is that rare occurrences are more subject to publication and reporting biases: the happy ending of a rare event prompts communication, while the opposite is true in cases of catastrophic events, such as the

loss of the mother and/or child. Hence, the evidence is heterogeneous and scant, with several case reports showing referral and publication biases, and few existing large series from reference Centres or Registries. Currently, despite growing interest in this topic, only the ANZDATA dialysis Registry gathers data on pregnancies in its core file, while the US Registry on Pregnancy and Dialysis is based upon voluntary contribution and the ERA-EDTA has only recently commenced a specific study on this issue, i.e. the DIAPER study [11, 17–19].

Therefore, while acknowledging the lack of RCTs (by necessity of the subject, i.e. pregnancy) and of large observational studies (due to the rarity of the event), we will here deal at best with GRADE IIa recommendations, though we also need to consider several non graded suggestions (which should not be underestimated) that may be seen as reflecting an ever-evolving situation [20–25].

The present position statement refers to a search strategy that was based on the June 2014 update of a previous systematic review on dialysis and pregnancy. Details on the search strategy and on the paper selection modality can be found in that review [5].

### **“Diagnosis” of pregnancy in dialysis**

1. The “diagnosis” of pregnancy in women on dialysis may be difficult, and the presence of the foetus and the gestational age should be verified by ultrasound examination (not graded).

The “diagnosis” of pregnancy in the dialysis setting may be difficult both because pregnancy is often unexpected and the symptoms in the early phase may mimic different diseases and complications of dialysis, and because serum levels of beta-hCG may be increased even in the absence of pregnancy [26, 27]. Furthermore, irregular menstrual cycles and anovulation are common in women on dialysis, thus making the calculation of gestational age based upon the last menstrual cycle unreliable [26]. In this context, early ultrasonography should be used to verify the presence of a viable foetus and to calculate the gestational age.

### **Timing of start of dialysis in pregnancy**

1. Initiate renal replacement therapy (RRT) when a good metabolic and fluid balance cannot be achieved by conservative treatment (not graded).
2. When deciding to start RRT, take into consideration the general clinical context including the presence of conditions that can be modified by dialysis, the trend of the subject’s laboratory tests, and control of

hypertension and fluid overload rather than creatinine-based thresholds alone (not graded).

3. Consider urea levels in the decision when to start dialysis: the blood urea nitrogen (BUN) test is considered a very important marker of outcomes when dialysis is already started. No threshold has been established for dialysis start (not graded).
4. Consider the phase of pregnancy in the decision, balancing the risks and benefits of dialysis start versus early delivery in late pregnancy (after the 28th and, more specifically, after the 34th gestational week) (not graded).
5. Low protein diets may be useful for postponing dialysis in selected cases with advanced chronic kidney disease (CKD) (not graded).

‘Life-threatening’ changes in fluid, electrolyte and acid–base balance that cannot be managed by conservative interventions are the main indications for dialysis start [28, 29]. The concept of “life-threatening” is, however, difficult to apply to pregnancy and no studies have specifically focused on this issue. One of the problems also is the limited reliability of estimated glomerular filtration rate (eGFR) assessment in pregnancy due to the lack of validated formulae [28–32].

The cases reported in the literature range from “early” dialysis start, at a GFR of about 20 ml/min, to a later start, in keeping with the most recent guidelines [18, 33, 34].

All the available data on dialysis start come from observational studies focusing on various outcomes. However, the impressive relationship between pregnancy-related outcomes and dialysis efficiency suggests that once dialysis is started treatment should be intensive [11–13].

The main benefits of RRT on metabolic control and on volume and blood pressure management versus the potentially negative effects on the mother and foetus should be weighed up on an individual basis. These drawbacks include catheter-related complications if dialysis is started with a central venous access, the need for surgical intervention and the stress related to fistula placement, haemorrhaging caused by anticoagulation therapy, and the risk of dialysis-related hypotension that may precipitate foetal–placental hypoperfusion, a feared side-effect of diuretics [33–35].

The risk–benefit balance may be different in the various phases of pregnancy, and the balance may be in favour of start of dialysis in early pregnancy, while the risks of dialysis should be carefully weighed against the risks of early delivery. This is especially true after the 34th completed gestational week, on account of the important reduction of major foetal risks after this term (the “late preterm period” is defined as 34–37 gestational weeks) [36–39]. Every effort should be made to prolong pregnancy as much as possible in the “grey” area in which viability is

possible but the risk of long-term problems is very high (“extremely preterm period”: 24–28 weeks) [38, 39].

According to the decade-long experience of a single nephrology and obstetrics group in managing severe CKD, a low-protein diet under strict clinical control may be useful for postponing dialysis in selected cases [40, 41].

These mostly experience-based opinions underline the need for further studies on the timing of dialysis start in pregnancy. Hence, the Study Group on Kidney and Pregnancy of the Italian Society of Nephrology encourages systematically including detailed indications for the start of dialysis (also with regard to the foetal situation) in reports on dialysis in pregnancy, and identifying control groups treated conservatively or with planned delivery before dialysis start.

### Haemodialysis or peritoneal dialysis in pregnancy?

1. In patients already on dialysis when the pregnancy starts, dialysis can be continued in the same mode provided that a good dialysis efficiency is reached (evidence from scattered reports).
2. For patients who need to start dialysis when a pregnancy is underway, the following issues should be taken into consideration: the patient’s preference, phase of pregnancy, expected dialysis efficiency, availability of intensive extracorporeal dialysis and risk of rapid loss of kidney function (not graded).

There are currently no studies specifically comparing peritoneal dialysis (PD) and extracorporeal dialysis (HD) in pregnancy, though some reports of pregnancies in association with both dialysis modalities are available in many large series or from registry data [5, 16–18, 42, 43].

The smaller number of cases reported for PD is at least partly a reflection of the overall lower prevalence of this technique. However, in the light of data on extracorporeal dialysis suggesting a close link between favourable outcomes and dialysis efficiency, the possibility of a negative effect of the lower dialysis efficiency should be taken into account.

The Study Group recommends taking the following issues into consideration when choosing the type of dialysis. The patient’s preference should be the main criteria for the choice, provided there are no contraindications for either method. The phase of pregnancy may be relevant, in particular in the late phases of pregnancy and even more so in specific diseases such as autosomal dominant polycystic kidney disease (ADPKD) in which abdominal filling may be critical and the risk of uterine injury may be increased due to mechanical reasons. Furthermore, with regard to dialysis start, due to the acknowledged importance of this

issue, the Italian Study Group suggests to consider the expected dialysis efficiency and the availability of intensive extracorporeal dialysis. To date, the best results published regarding pregnancy in RRT were obtained with long-hour daily dialysis; therefore we suggest considering this as first choice, when available, although there is no evidence suggesting that “less intensive” extracorporeal schedules and intensive PD may lead to different pregnancy-related outcomes [11, 12]. A further issue may be the risk of rapid loss of residual renal function, which is expected to be higher with HD than with PD. This point in favour of PD should be evaluated also bearing in mind the previous decline of residual renal function, as this is expected to be more relevant in chronic interstitial diseases in which, outside of pregnancy, the loss of kidney function is usually slower than in primary or secondary glomerular diseases [44, 45].

Conversely, the disadvantages of each of the two therapies, namely, the risk of peritonitis and lower efficiency of PD, on the one hand, and the risk of overly rapid fluid and electrolyte shifts, of anticoagulation and the higher intrusiveness in one’s daily life of HD, on the other, should be mentioned in counselling.

There is a strong need for prospective observational comparative studies on this issue. The Italian Study Group suggests adding data regarding pregnancy to the yearly update of dialysis registries.

### Dialysis schedule for haemodialysis

1. Haemodialysis is the standard extracorporeal treatment in pregnancy; few data are available regarding haemodiafiltration, thus suggesting at least equal benefits (not graded).
2. Haemodialysis intensity (frequency and duration) should be increased in pregnancy (strong recommendation, good quality observational evidence).
3. Quotidian or nightly dialysis (6–7 days per week) should be offered at least to patients without residual renal clearance (strong recommendation, good quality observational evidence).
4. Since pregnancy outcome improves as the number of dialysis hours increases, reaching statistical significance at or above 36 h per week (85 % probability of success), we suggest tailoring the number of hours needed to reach this minimum goal as quickly as possible (strong recommendation, good quality observational evidence).
5. We recommend adapting the prescription of bicarbonate, potassium and calcium to the individual patient, with particular attention to slow fluid removal and to the progressive increase in weight during pregnancy (not graded).
6. We do not recommend using Kt/V or equivalent renal clearance as a measure of dialysis in pregnancy due to the lack of studies evaluating these markers; pre-dialysis BUN levels (<50 mg/dl) or urea levels (<100 mg/dl) may be used as a surrogate (not graded).

Due to the rarity of pregnancy during dialysis, to the scattered data and to the varying availability of dialysis all over the world, there is a considerable lack of data on extracorporeal dialysis other than bicarbonate dialysis, even though from a theoretical point of view haemodiafiltration may be more suited to pregnancy given the high tolerance and better removal of middle molecules afforded by this method. There are few reports in the literature regarding this dialysis modality, overall suggesting that haemodiafiltration may be (at least) equal to haemodialysis in pregnancy [46–49].

Long, highly efficient daily haemodialysis treatments have been increasingly used in pregnancy. The best results on dialysis, at least in cases without residual kidney function, have been reported in long-hour daily dialysis [5, 11–13, 18, 46–56].

The use of Kt/V or urea levels for tailoring dialysis is not recommended since none of these measurements has been validated in pregnancy and their role as markers of “optimal efficiency” is clearly not applicable to pregnancy, a situation in which available data suggest a policy of “the more the better” [5, 11–13, 46–56]. A pre-dialysis urea level below 100 mg/dl may be considered a useful surrogate marker on the basis of the Canadian experience with long-hour daily dialysis [11–13].

Normal pregnancy is a hyperdynamic hyperhydrated state; this should be kept in mind when tailoring weight loss on dialysis. The usual markers of hydration in dialysis, i.e. blood pressure or muscle cramps, may be altered in pregnancy, the former by physiological vasodilation, the latter by the frequent occurrence of cramps in pregnancy, even in the absence of evident electrolyte disorders. None of the other means of establishing the “dry weight”, including bioimpedance or brain natriuretic peptide levels, has been validated in pregnancy. Hence, we suggest tailoring the decision on the type of dialysis to the individual patient, taking into account the usual tools available for assessment in each Unit and the specific experience of the clinicians.

Once more, the Study Group encourages systematically including detailed information of the dialysis schedules in all future studies to allow better contextualization of the results.

## Dialysis schedule for peritoneal dialysis

1. What the “ideal” type of peritoneal dialysis is—continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD)—remains to be determined (not graded).
2. Dialysis efficiency has to be increased to provide increased solute clearance in women on PD who are pregnant (not graded).
3. In CAPD, the peritoneal dialysis prescription should be modified by increasing the *number* of exchanges rather than the exchange volume since large volumes are not well tolerated, especially during the third trimester (not graded).
4. In APD, the dialysis prescription should be modified with an increase in the total volume and prolonged time, reducing dwell volumes and increasing the number of cycles (not graded).
5. In APD, tidal peritoneal dialysis can be used to avoid drain pain and reduce gastro-oesophageal reflux. Tidal regimens may also alleviate catheter drain dysfunction caused by the expanding uterus (not graded).
6. We do not recommend using Kt/V and/or peritoneal creatinine clearance as a measurement of dose of dialysis in pregnancy due to the lack of studies considering these markers with respect to pregnancy outcomes (not graded).

There are fewer studies on PD as compared to HD: conception rate is reported as being lower in PD patients, even though the reported ranges are broad, as was also recently confirmed by the ANZDATA Registry [3, 4, 17, 40, 57–68]. This lower conception rate has been attributed to several factors, including the presence of hypertonic dialysate in the peritoneum, prior episodes of peritonitis and the inability of the ovum to reach the fallopian tubes in the presence of intraperitoneal dialysate [44, 69].

Dialysis prescriptions should be tailored to increase peritoneal clearance, mainly by acting on the frequency and/or duration of dwell, avoiding an increase in volumes, and taking abdominal fullness into account [3, 4, 17, 44, 57–69].

Several advantages and disadvantages of PD have been reported: some authors have suggested that the main disadvantages include: abdominal fullness with the possibility of catheter displacement, drain pain, dialysate flow disturbance and gastro-oesophageal reflux. Haemoperitoneum is an infrequent and usually benign occurrence in patients treated with peritoneal dialysis that is occasionally reported in pregnancy. Management strategies include increased exchanges and cooled dialysate. Severe haemoperitoneum that does not clear may be a sign of uterine trauma, uteroplacental detachment, placenta previa, or spontaneous

abortion [60, 67–70]. The incidence of peritonitis is not reported as being higher than what is observed in patients who are not pregnant [67–70].

Conversely, peritoneal dialysis offers some advantages: continuous treatment with smoother urea removal and stable metabolic balance without the fluctuations that are typical of the intermittent therapies; gentle daily ultrafiltration, minimizing changes in maternal intravascular volumes without the acute fluctuations that can compromise placental blood flow. Other potential benefits may be had by avoiding systemic anticoagulation, and possibly by following a more liberal diet, at least with regard to the many potassium rich foods.

When caesarean section is required, and if it is performed extraperitoneally, peritoneal dialysis can be resumed with small dwell volumes after 24 h, otherwise the mother should be temporarily switched to haemodialysis [71].

## Diet and weight management

1. The patient’s diet should be unrestricted and rich in proteins (supported by several experts; not graded).
2. Phosphate supplements may be needed on long-hour daily haemodialysis (not graded).
3. Soluble vitamin levels should be controlled and supplemented when needed (not graded).
4. Weight gain should be carefully monitored, trying to avoid dehydration and hypotension. Weight gain is estimated at 300 g/week during the second trimester and 300–500 g/week in the third trimester (not graded).

Nutritional support is mentioned in several papers, and overall the most common advice is either an unrestricted diet or a high protein diet [3, 11–13, 49, 50, 53, 72–74]. Nutritional supplements of phosphate may be needed in patients treated with high efficiency, long-hour dialysis, while water-soluble vitamins should always be checked in all patients and supplemented when needed. While daily, high efficiency dialysis is increasingly being prescribed, it usually suffices to correct acidosis and restore a positive calcium balance, although other trace elements, including zinc, may be deficient and should be kept under control and supplemented if necessary [11–13, 75].

The limits of these indications are linked to the fact that different nutrients are reported across the various studies, and that there is no shared list of vitamins and microelements that should be controlled. In the absence of precise indications, the Italian Study Group suggests including detailed testing and supplementation policies in studies on pregnant women on dialysis.

## Control policies

1. We recommend strict clinical control for all patients (not graded).
2. The frequency of visits should be personalized; weekly laboratory controls are recommended to tailor dialysis schedules (not graded).
3. We do not suggest pre-emptive hospitalization except for obstetrics-related reasons (not graded).
4. Obstetric and nephrological visits should be combined to minimize stress on the patient (not graded).
5. Foetal monitoring should be intensified (supported by all experts; not graded).

Again, there is no specific evidence available on this very important clinical issue. Very few papers report the frequency of visits in detail and, in the few papers that do report on them, the non homogeneity of policies for the management of chronic dialysis patients is evident [3–13, 16–18, 43, 44, 50–53].

In this context, the opinion of the Italian Study Group is that intensifying dialysis requires concomitantly intensifying clinical and biochemical testing. The tests, which are usually linked to the dialysis session (creatinine, urea, electrolytes, complete blood cell count, acid base balance, serum albumin), should be performed at least twice monthly in stable patients. However, the frequency may be further increased in specific patients and in Centres having less experience with quotidian dialysis treatments.

The reported obstetrics control policy is highly heterogeneous, following the general changes that have taken place in obstetrics policies over time. Older papers underline the importance of uterine and foetal monitoring at each dialysis session [53–56, 69–73]. Conversely, more recent studies report less stringent controls, such as ultrasounds every 1–2 weeks or more frequently as the patient nears term, or when pregnancy complications are encountered. Some authors also suggest including serial cervical length measurements [6, 7, 11, 54]. Recent studies underline the importance of Doppler measurements every 1–3 weeks [6, 7, 11, 55, 56]. In such context, even taking into account the different policies in the various obstetric referral centres, our Study Group suggests contextualizing the control policy with the obstetricians.

## Main drug treatments: anaemia

1. Anaemia should be managed with erythropoietin stimulating agents (ESAs) and vitamins. The haemoglobin target should be 10–11 g/dl. ESA doses frequently need to be increased in pregnant dialysis

- patients (strong suggestion from large studies on CKD patients not on dialysis).
2. The demand for iron is increased in pregnancy in dialysis. Oral iron administration is safe in pregnant women on dialysis, while intravenous (i.v.) iron should be managed with care in dialysis mothers (strong suggestion from large studies in CKD patients not on dialysis and in non CKD patients).
3. Folate and B<sub>12</sub> supplementation should be tailored according to blood levels (not graded).

Anaemia is a frequent complication in pregnant dialysis patients [3–5]. However, most of the information from the large series regards patients not on dialysis. Maternal anaemia has been correlated with infant mortality, preterm labour and foetal loss in large series of non-dialysis patients [76–81]. Erythropoietin has been shown to be safe and non-teratogenic in pregnancy [79–81]. Erythropoietin doses should be increased by 50–100 % in an attempt to achieve targeted haemoglobin levels above 10–11 g/dl, with haematocrit concentrations above 30–35 % [5, 13, 27].

The need for iron, which is already an issue in healthy pregnant women, may be higher in pregnant women on dialysis [69]. Oral iron administration is safe in pregnancy, although it is often not sufficient to compensate for the increased need: supplementation should start as soon as possible in the presence of even only a mild deficiency and normal haemoglobin levels [82–86]. In refractory cases, intravenous iron, targeted at transferrin saturation levels above 30 %, has been given to pregnant dialysis patients without adverse events [13, 82–86]. However, in the later stages of pregnancy, up to 80–90 % of parenteral iron may be deposited in the foetus; thus it should be given in small doses [69]. Folate and B<sub>12</sub> should be checked and supplemented in the case of low blood levels at doses adjusted to reach appropriate levels in the blood [69].

## Main drug treatments: calcium-phosphate balance

1. Vitamin D supplementation is safe in pregnancy and may be required at increased doses (strong suggestion from large studies in non-dialysis patients).
2. Calcium-containing phosphate binders are safe (not graded), while sevelamer may negatively affect foetal ossification (evidence from animal studies).
3. Attention should also be paid to magnesium levels since low levels may favour uterine contraction (strong suggestion from large studies in non-dialysis patients).

The need for vitamin D supplementation is increasingly acknowledged in pregnancy [87–90]. In pregnant dialysis patients the usual vitamin D needs may be increased

because of placental 25-hydroxyvitamin D<sub>3</sub> conversion [91]. In dialysis patients, vitamin D supplementation should be guided by levels of mono and di-hydroxylated vitamin D, calcium and phosphate [92]. Calcium supplements or calcium-based binders are safe, but their use may not be needed if high dialysis efficiency is attained, while sevelamer should not be used in pregnancy because animal studies have shown irregular ossification of foetal bones [91, 92].

Magnesium is a tocolytic and low serum levels may induce uterine contractions. Serum magnesium levels should be maintained at 5–7 mg/dl; oral magnesium supplementation may be required [91, 93].

Other drug treatments, such as hypotensives or aspirin, will be discussed in the next consensus statement on CKD and pregnancy.

### **Counselling tips for dialysis or pre-dialysis patients who wish to undertake a pregnancy**

1. Counselling on pregnancy and contraception should be included in the approach to all women in childbearing age who start dialysis (not graded).
2. Extensive counselling is needed to guide the choice of a woman on dialysis whether to undertake or continue pregnancy (not graded).
3. The prognostic markers allowing quantification of the probability of a successful pregnancy are only partially known. Residual kidney function and normotension are favourable prognostic factors (not graded).
4. Counselling should also include the fact that outcomes of pregnancy are better after transplantation than on dialysis (strong suggestion from large studies in transplanted patients, and from Registries).
5. The main risks for the child are those linked to prematurity. No increase in congenital malformations has been reported (not graded).

Counselling is a crucial part of the care of a pregnant woman on dialysis and should be systematically undertaken before pregnancy and possibly also before the start of dialysis [5, 74, 94]. Counselling on pregnancy is closely linked to counselling on contraception, as the effect of an unwanted pregnancy may be disruptive on a woman on dialysis. With regard to the indications for clinical counselling, it should be extensive and should cover the most important evidence, as well as the limits of the current knowledge and experience. According to the Study Group, the following issues should be covered: pregnancy on dialysis is possible and the reported success rate has been over 70–80 % in the last decade [5–13]. However, evidence is scant, and there is probably a bias of reporting

only the “happy endings”, at least in smaller case series. The risk of death for the mother is very low with no deaths being reported in the most recent large series [5–13]. The risk of foetal loss and of neonatal death is higher than in pregnancy after transplantation and is higher in both cases with respect to the overall population [16, 17].

Prematurity is the main risk for the baby. Besides the presence of hereditary kidney diseases, there is no evidence suggesting that the number of congenital malformations is higher in children born to dialysis mothers. The risk of prematurity is, however, very high and decreases along with the increase of dialysis frequency and time on dialysis [5–13, 16, 17, 42, 95]. In the very few studies reporting long-term outcomes in children, normal psychosocial skills have been reported in most cases [16, 44]. Considering the importance of this subject, the Italian Study Group strongly suggests the need for further studies on the long-term prognosis of mothers and children.

Dialysis care in pregnancy is highly demanding: there is a need to increase the number and duration of haemodialysis sessions, with an ideal target of at least 36 h per week. Even if there is no need a priori to change the dialysis modality if the mother is on PD, (but even in this case) efficiency should be increased as much as possible, and a shift to haemodialysis may be needed if metabolic control is suboptimal [5–13, 16, 17, 49–52].

The presence of residual renal function is reported as being correlated to better pregnancy related outcomes, as is a shorter dialysis vintage and the starting of dialysis during the course of pregnancy (as opposed to conception occurring when dialysis is underway) [16–18]. However, pregnancy is also possible in patients with long-term dialysis vintage, no residual kidney function and immunological diseases [16, 18].

In spite of the growing number of cases reported in the literature, the Working Group underlines that patients should be made aware that clinical experience is still limited and that even the largest referral Centres have dealt with a very limited number of cases.

Patients should also be advised that the probability of a successful at, or near, term pregnancy is significantly higher in patients after transplantation than in patients on dialysis. This may support the choice of postponing pregnancy until after kidney transplantation, at least in patients who are young and have a high probability of receiving a kidney graft [16, 17, 96–98].

Despite all these limits, dialysis patients may benefit from all the advantages that have been reported in maternal-foetal medicine in the last decades, and the outcomes of pregnancy on dialysis have improved in all studied settings in the new millennium due to well-established cooperation between the Nephrology team and tertiary Obstetrics care Centre.

**Acknowledgments** The project received the support of ANED (National Association of Dialysis and Transplanted Patients).

**Conflict of interest** The authors declare they have no conflict of interest.

**Ethical approval** This article does not contain any studies with human participants performed by any of the authors.

## Appendix: Working Group on Dialysis and Pregnancy

Santina Castellino (sancas@tin.it) UO Nefrologia Ospedale di Taormina (CT); Giuseppe Gernone (g.ger@libero.it) Azienda Sanitaria Locale Bari Putignano (BA); Bruna Guida (bguida@unina.it) Physiology Nutrition Unit, Department of Clinical Medicine and Surgery, Federico II University, Napoli; Santo Calabria (calabria.dr@gmail.com) and Marco Galliani (marco.galliani@aslromab.it) UO Nefrologia Dialisi e Litotrissia Ospedale ‘Sandro Pertini’ Roma; Gianfranco Manisco (g.manisco@yahoo.it), Massimo di Tullio (mditullio@libero.it) and Luigi Vernaglione UO Nefrologia e Dialisi Ospedale Camberlingo Francavilla Fontana (BR); Maria Grazia Chiappini (maria.chiappini@tin.it) and Emanuela Proietti (e.proietti@live.it) UO Nefrologia e Dialisi S.Giovanni Calibita Fatebenefratelli Roma; Stefano Saffiotti (stesaf@unige.it) Clinica Nefrologia Dialisi e Trapianto IRCCS S.Martino di Genova (GE); Concetta Gangeni (conceceta.gangeni@ospedaleuniverona.it) UO Nefrologia e Dialisi, Ospedale Civile Maggiore Verona (VR); Chiara Brunati (chiara.brunati@ospedaleniguarda.it) and Alberto Montoli (alberto.montoli@ospedaleniguarda.it) UO Nefrologia Dialisi e Trapianti ASO Niguarda Ca’Granda Milano (MI); Ciro Esposito (espositociro56@live.it) and Giovanni Montagna (giovanni.montagna@fsm.it) UO Nefrologia e Dialisi Fondazione Salvatore Maugeri di Pavia (PV); Salvatore Tata (toff@iol.it) and Paolo Romano (paolo.romano@ulss12.ve.it) UO Nefrologia e Dialisi Ospedale dell’Angelo Mestre (VE); Ottavio Amatruda (oamatruda@gmail.com) and Paolo Cervini (paolo.cervini@ospedale.varese.it) UO Nefrologia, Dialisi e Trapianto Azienda Ospedaliera Macchi Varese (VA); Erika Casiraghi (erika.casiraghi@gmail.com) and Federico Pieruzzi (federico.pieruzzi@unimib.it) Clinica Nefrologica Università Milano-Bicocca (MI); Attilio Di Benedetto (attilio.dibenedetto@fmc-ag.com) and Giuseppina Alfisi Centro NephroCare Polla (SA); Marco Heidempergher (heidempergher.marco@hsacco.it) and Monique Buskermolen (buskermolen.monique@hsacco.it) UO Nefrologia e Dialisi ASO L. Sacco Milano (MI); Alessandro Leveque (alessandro.leveque@uslumbria1.it) and Valerie Autuly UO Nefrologia e Dialisi Presidio Ospedaliero USL1 Citta’ di Castello (PG); Francesco Giofre’ (giofre.fr@aslvv.it) and

Giovanni Alati (giovanni.alati@alice.it) UO Nefrologia Dialisi Ospedale Vibo Valentia Tropea (RC); Luigi Lombardi (nefrologia.lombardi@libero.it) UO Nefrologia Dialisi ASO A. Pugliese- Ciaccio Catanzaro (CZ); Mara Riccio and Ivano Riccio (info@gruppoidsama.it) I.SA.MA. SRL ASL 670 SA Sant’Egidio del Monte Albino (SA); Antonio Stingone (stingant@libero.it) and Benito D’Angelo U.O. di Nefrologia e Dialisi Ospedale G. Bernabeo Ortona; Leonardo Lucchi (lucchi.leonardo@policlinico.mo.it) and Lucia Stipo UOC di Nefrologia Dialisi e Trapianti AOU di Modena-Policlinico.

## References

1. Confortini P, Galanti G, Ancona G, Giungio A, Bruschi E, Lorenzini E (1971) Full-term pregnancy and successful delivery in a patient on chronic hemodialysis. *Proc Eur Dial Transplant Assoc* 8:74–80
2. Hou S (2007) Historical perspective of pregnancy in chronic kidney disease. *Adv Chronic Kidney Dis* 14(2):116–118
3. Holley JL, Reddy SS (2003) Pregnancy in dialysis patients: a review of outcomes, complications, and management. *Semin Dial* 16(5):384–388
4. Hou S (2010) Pregnancy in women treated with dialysis: lessons from a large series over 20 years. *Am J Kidney Dis* 56(1):5–6
5. Piccoli GB, Conijn A, Consiglio V et al (2010) Pregnancy in dialysis patients: is the evidence strong enough to lead us to change our counseling policy? *Clin J Am Soc Nephrol* 5(1):62–71
6. Luders C, Castro MC, Titan SM et al (2010) Obstetric outcome in pregnant women on long-term dialysis: a case series. *Am J Kidney Dis* 56(1):77–85
7. Bahadi A, El Kabbaj D, Guelzim K et al (2010) Pregnancy during hemodialysis: a single center experience. *Saudi J Kidney Dis Transpl.* 21(4):646–651
8. Al-Saran KA, Sabry AA (2008) Pregnancy in dialysis patients: a case series. *J Med Case Rep* 20(2):10
9. Chou CY, Ting IW, Lin TH, Lee CN (2008) Pregnancy in patients on chronic dialysis: a single center experience and combined analysis of reported results. *Eur J Obstet Gynecol Reprod Biol* 136(2):165–170
10. Malik GH, Al-Harbi A, Al-Mohaya S (2005) Pregnancy in patients on dialysis—experience at a referral center. *J Assoc Physicians India* 53:937–941
11. Hladunewich MA, Hou S, Oduyayo A et al (2014) Intensive hemodialysis associates with improved pregnancy outcomes: a canadian and United States cohort comparison. *J Am Soc Nephrol* 25(5):1103–1109
12. Barua M, Hladunewich M, Keunen J et al (2008) Successful pregnancies on nocturnal home hemodialysis. *Clin J Am Soc Nephrol* 3(2):392–396
13. Nadeau-Fredette AC, Hladunewich M, Hui D, Keunen J, Chan CT (2013) End-stage renal disease and pregnancy. *Adv Chronic Kidney Dis* 20(3):246–252
14. Small N, Bower P, Chew-Graham CA, Whalley D, Protheroe J (2013) Patient empowerment in long-term conditions: development and preliminary testing of a new measure. *BMC Health Serv Res* 13:263
15. Aujoulat I, d’Hoore W, Deccache A (2007) Patient empowerment in theory and practice: polysemy or cacophony? *Patient Educ Couns* 66(1):13–20



16. Piccoli GB, Cabiddu G, Daidone G, Italian Study Group “Kidney and Pregnancy” et al (2014) The children of dialysis: live-born babies from on-dialysis mothers in Italy—an epidemiological perspective comparing dialysis, kidney transplantation and the overall population. *Nephrol Dial Transplant* 29(8):1578–1586
17. Shahir AK, Briggs N, Katsoulis J, Levidiotis V (2013) An observational outcomes study from 1966–2008, examining pregnancy and neonatal outcomes from dialysed women using data from the ANZDATA Registry. *Nephrology (Carlton)* 18(4):276–284
18. Jesudason S, Grace BS, McDonald SP (2014) Pregnancy outcomes according to dialysis commencing before or after conception in women with ESRD. *Clin J Am Soc Nephrol* 9(1):143–149
19. <http://www.era-edta-reg.org>. Accessed 1 Mar 2015
20. Lawlor DA, Davey Smith G, Bruckdorfer KR, Kundu D, Ebrahim S (2004) Observational versus randomised trial evidence. *Lancet* 364(9436):755
21. Booth CM, Tannock IF (2014) Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. *Br J Cancer* 110(3):551–555
22. Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. *N Engl J Med* 342:1878–1886
23. Concato J, Shah N, Horwitz RI (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. *N Engl J Med* 342(25):1887–1892
24. Barton S (2000) Which clinical studies provide the best evidence? The best RCT still trumps the best observational study. *BMJ* 321:255–256
25. Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, GRADE Working Group et al (2004) Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches. The GRADE Working Group. *BMC Health Serv Res* 4(1):38
26. Hou S (1999) Pregnancy in chronic renal insufficiency and end-stage renal disease. *Am J Kidney Dis* 33(2):235–252
27. Piccoli G, Bontempo S, Mezza E et al (2004) Sudden development of low tolerance of dialysis in a young female patient. *Nephrol Dial Transplant* 19(1):255–257
28. Nesrallah GE, Mustafa RA, Clark WF et al (2014) Canadian Society of Nephrology. Canadian Society of Nephrology 2014 clinical practice guideline for timing the initiation of chronic dialysis. *CMAJ* 186(2):112–117
29. Tattersall J, Dekker F, Heimbürger O et al (2011) ERBP Advisory Board. When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study. *Nephrol Dial Transplant* 26(7):2082–2086
30. Koetje PM, Spaan JJ, Kooman JP, Spaanderman ME, Peeters LL (2011) Pregnancy reduces the accuracy of the estimated glomerular filtration rate based on Cockcroft–Gault and MDRD formulas. *Reprod Sci* 18:456–462
31. Ahmed SB, Bentley-Lewis R, Hollenberg NK, Graves SW, Seely EW (2009) A comparison of prediction equations for estimating glomerular filtration rate in pregnancy. *Hypertens Pregnancy* 28(3):243–255
32. Morken NH, Travlos GS, Wilson RE, Eggesbø M, Longnecker MP (2014) Maternal glomerular filtration rate in pregnancy and fetal size. *PLoS ONE* 9(7):e101897
33. Sato JL, De Oliveira L, Kirsztajn GM, Sass N (2010) Chronic kidney disease in pregnancy requiring first-time dialysis. *Int J Gynaecol Obstet* 111:45–48
34. Cornelis T, Spaanderman M, Beerenhout C et al (2013) Antiangiogenic factors and maternal hemodynamics during intensive hemodialysis in pregnancy. *Hemodial Int* 17:639–643
35. Al Khaja KA, Sequeira RP, Alkhaja AK, Damanhori AH (2014) Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. *J Hypertens* 32:454–463
36. Vohr B (2013) Long-term outcomes of moderately preterm, late preterm, and early term infants. *Clin Perinatol* 40:739–751
37. Machado LC Jr, Passini R Jr, Rosa IR, Carvalho HB (2014) Neonatal outcomes of late preterm and early term birth. *Eur J Obstet Gynecol Reprod Biol* 179:204–208
38. Ge WJ, Mirea L, Yang J, Bassil KL, Lee SK, Shah PS, Canadian Neonatal Network (2013) Prediction of neonatal outcomes in extremely preterm neonates. *Pediatrics* 132:e876–e885
39. Boland RA, Davis PG, Dawson JA, Doyle LW, Victorian Infant Collaborative Study Group (2013) Predicting death or major neurodevelopmental disability in extremely preterm infants born in Australia. *Arch Dis Child Fetal Neonatal Ed* 98:F201–F204
40. Piccoli GB, Leone F, Attini R et al (2014) Association of low-protein supplemented diets with fetal growth in pregnant women with CKD. *Clin J Am Soc Nephrol* 9:864–873
41. Piccoli GB, Attini R, Vasario E et al (2011) Vegetarian supplemented low-protein diets. A safe option for pregnant CKD patients: report of 12 pregnancies in 11 patients. *Nephrol Dial Transplant* 26:196–205
42. Abou-Jaoude P, Dubourg L, Bessenay L et al (2012) What about the renal function during childhood of children born from dialysed mothers? *Nephrol Dial Transplant* 27:2365–2369
43. Okundaye I, Abrinko P, Hou S (1998) Registry of pregnancy in dialysis patients. *Am J Kidney Dis* 31:766–773
44. Dimitriadis CA, Bargman JM (2011) Gynecologic issues in peritoneal dialysis. *Adv Perit Dial* 27:101–105
45. Shemin D, Bostom AG, Lambert C, Hill C, Kitsen J, Klinger AS (2000) Residual renal function in a large cohort of peritoneal dialysis patients: change over time, impact on mortality and nutrition. *Perit Dial Int* 20:439–444
46. Mm A, Ms A, Oi A (2014) Lupus flares in two established end-stage renal disease patients with on-line hemodiafiltration during pregnancy—case series. *Lupus* 23:945–948
47. Haase M, Morgera S, Bamberg C et al (2005) A systematic approach to managing pregnant dialysis patients—the importance of an intensified haemodiafiltration protocol. *Nephrol Dial Transplant* 20:2537–2542
48. Haase M, Morgera S, Bamberg C et al (2006) Successful pregnancies in dialysis patients including those suffering from cystinosis and familial Mediterranean fever. *J Nephrol* 19: 677–681
49. Asamiya Y, Otsubo S, Matsuda Y et al (2009) The importance of low blood urea nitrogen levels in pregnant patients undergoing hemodialysis to optimize birth weight and gestational age. *Kidney Int* 75:1217–1222
50. Ståhl M, Wendt M, Mielniczenko G, Sennström M, Fehrman-Ekholm I (2014) Pregnancy and childbirth is now possible for women with chronic kidney disease. Dialysis treatment should be intensified during pregnancy, as shown in five cases. *Lakartidningen* 111:154–157
51. Hadj Sadek B, Kejjj S, Rhou H, Ezzaitouni F, Ouzeddoun N, Bayahia R, Benamar L (2011) Pregnancy in chronic hemodialysis patients. *J Gynecol Obstet Biol Reprod (Paris)* 40:452–459
52. Bamberg C, Diekmann F, Haase M, Budde K, Hocher B, Halle H, Hartung J (2007) Pregnancy on intensified hemodialysis: fetal surveillance and perinatal outcome. *Fetal Diagn Ther* 22:289–293
53. Eroğlu D, Lembed A, Ozdemir FN, Ergin T, Kazanci F, Kuşcu E, Haberal M (2004) Pregnancy during hemodialysis: perinatal outcome in our cases. *Transplant Proc* 36:53–55
54. Bahloul H, Kammoun K, Kharrat M et al (2003) Pregnancy in chronic hemodialysis women: outcome of multicentric study. *Saudi J Kidney Dis Transpl* 14:530–531
55. Chao AS, Huang JY, Lien R, Kung FT, Chen PJ, Hsieh PC (2002) Pregnancy in women who undergo long-term hemodialysis. *Am J Obstet Gynecol* 187:152–156

56. Luciani G, Bossola M, Tazza L et al (2002) Pregnancy during chronic hemodialysis: a single dialysis-unit experience with five cases. *Ren Fail* 24:853–862
57. Jefferys A, Wyburn K, Chow J, Cleland B, Hennessy A (2008) Peritoneal dialysis in pregnancy: a case series. *Nephrology* 13:380–383
58. Smith WT, Darbari S, Kwan M, O'Reilly-Green C, Devita MV (2005) Pregnancy in peritoneal dialysis: a case report and review of adequacy and outcomes. *Int Urol Nephrol* 37:145–151
59. Chang H, Miller MA, Bruns FJ (2002) Tidal peritoneal dialysis during pregnancy improves clearance and abdominal symptoms. *Perit Dial Int* 22:272–274
60. Batarse R, Steiger RM, Guest S (2014) Peritoneal dialysis prescription during the third trimester of pregnancy. *Perit Dial Int* (Epub ahead of print)
61. Sivasuthan G, Dahwa R, John GT, Ranganathan D (2013) Dialysis and pregnancy in end stage kidney disease associated with lupus nephritis. *Case Rep Med* 2013:923581
62. Abu-Zaid A, Nazer A, Alomar O, Al-Badawi IA (2013) Successful pregnancy in a 31-year-old peritoneal dialysis patient with bilateral nephrectomy. *Case Rep Obstet Gynecol* 2013:173405
63. Inal S, Reis KA, Armağan B, Oneç K, Biri A (2012) Successful pregnancy in an end-stage renal disease patient on peritoneal dialysis. *Adv Perit Dial* 28:140–141
64. Gómez Vázquez JA, Martínez Calva IE, Mendiola Fernández R, Escalera León V, Cardona M, Noyola H (2007) Pregnancy in end-stage renal disease patients and treatment with peritoneal dialysis: report of two cases. *Perit Dial Int* 27:353–358
65. Asgari E, Bramham K, Shehata H, Makanjuola D (2007) Successful pregnancy in a patient with end-stage renal failure secondary to HIV nephropathy on peritoneal dialysis. *Nephrol Dial Transplant* 22:3671
66. Altay M, Akay H, Parpucu H, Duranay M, Oguz Y (2007) A rare case: full-term delivery in a lupus patient on CAPD. *Perit Dial Int* 27:711–712
67. Lew SQ (2006) Persistent hemoperitoneum in a pregnant patient receiving peritoneal dialysis. *Perit Dial Int* 26:108–110
68. Chou CY, Ting IW, Hsieh FJ, Lee CN (2006) Haemoperitoneum in a pregnant woman with peritoneal dialysis. *Nephrol Dial Transplant* 21:1454–1455
69. Reddy SS, Holley JL (2007) Management of the pregnant chronic dialysis patient. *Adv Chronic Kidney Dis* 14(2):146–155
70. Tuncer M, Trak B, Sapan M, Ozcan S, Süleymanlar G, Yakupoglu G, Ersoy FF (2000) Successful pregnancy complicated with peritonitis in a 25-year-old Turkish CAPD patient. *Perit Dial Int* 20:349–350
71. Tan LK, Kanagalingam D, Tan HK, Choong HL (2006) Obstetric outcomes in women with end-stage renal failure requiring renal dialysis. *Int J Gynaecol Obstet* 94:17–22
72. Espinoza F, Romeo R, Ursu M, Tapia A, Vukusich A (2013) Pregnancy during dialysis: experience in six patients. *Rev Med Chil* 141:1003–1009
73. Giatras I, Levy DP, Malone FD, Carlson JA, Jungers P (1998) Pregnancy during dialysis: case report and management guidelines. *Nephrol Dial Transplant* 13:3266–3272
74. Watnick S (2007) Pregnancy and contraceptive counseling of women with chronic kidney disease and kidney transplants. *Adv Chronic Kidney Dis* 14:126–131
75. Tonelli M, Wiebe N, Hemmelgarn B, Alberta Kidney Disease Network et al (2009) Trace elements in hemodialysis patients: a systematic review and meta-analysis. *BMC Med* 19(7):25
76. Levy A, Fraser D, Katz M, Mazor M, Sheiner E (2005) Maternal anemia during pregnancy is an independent risk factor for low birthweight and preterm delivery. *Eur J Obstet Gynecol Reprod Biol* 122:182–186
77. American College of Obstetricians and Gynecologists (2008) ACOG Practice Bulletin No. 95: anemia in pregnancy. *Obstet Gynecol* 112:201–207
78. Allen LH (2000) Anemia and iron deficiency: effects on pregnancy outcome. *Am J Clin Nutr* 71(5 Suppl):1280S–1284S
79. Sienas L, Wong T, Collins R, Smith J (2013) Contemporary uses of erythropoietin in pregnancy: a literature review. *Obstet Gynecol Surv* 68:594–602
80. Horowitz KM, Ingardia CJ, Borgida AF (2013) Anemia in pregnancy. *Clin Lab Med* 33:281–291
81. Reddy SS, Holley JL (2009) The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis. *Kidney Int* 75:1133–1134
82. Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A (2005) Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. *Obstet Gynecol* 106:1335–1340
83. Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW, Nutrition Impact Model Study Group (anaemia) (2013) Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. *BMJ* 346:f3443
84. Peña-Rosas JP, De-Regil LM, Dowswell T, Viteri FE (2012) Daily oral iron supplementation during pregnancy. *Cochrane Database Syst Rev* 12:CD004736
85. Christoph P, Schuller C, Studer H, Irion O, De Tejada BM, Surbek D (2012) Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. *J Perinat Med* 40:469–474
86. Devasenapathy N, Neogi SB, Zodpey S (2013) Is intravenous iron sucrose the treatment of choice for pregnant anemic women? *J Obstet Gynaecol Res* 39:619–626
87. Harvey NC, Holroyd C, Ntani G et al (2014) Vitamin D supplementation in pregnancy: a systematic review. *Health Technol Assess* 18:1–190
88. De-Regil LM, Palacios C, Ansary A, Kulier R, Peña-Rosas JP (2012) Vitamin D supplementation for women during pregnancy. *Cochrane Database Syst Rev* 2:CD008873
89. McAree T, Jacobs B, Manickavasagar T et al (2013) Vitamin D deficiency in pregnancy—still a public health issue. *Matern Child Nutr* 9:23–30
90. Yu CK, Sykes L, Sethi M, Teoh TG, Robinson S (2009) Vitamin D deficiency and supplementation during pregnancy. *Clin Endocrinol (Oxf)* 70(5):685–690
91. Podymow T, August P, Akbari A (2010) Management of renal disease in pregnancy. *Obstet Gynecol Clin North Am* 37(2):195–210
92. Hladunewich M, Hercz AE, Keunen J, Chan C, Pierratos A (2011) Pregnancy in end stage renal disease. *Semin Dial* 24(6):634–639
93. Schoenaker D, Soedamah-Muthu SS, Mishra GD (2014) The association between dietary factors and gestational hypertension and pre-eclampsia: a systematic review and meta-analysis of observational studies. *BMC Med* 12(1):157
94. Bramham K, Lightstone L (2012) Pre-pregnancy counseling for women with chronic kidney disease. *J Nephrol* 25:450–459
95. Vázquez-Rodríguez JG, del Angel-García G (2010) Perinatal complications in patients with chronic renal insufficiency on hemodialysis. *Ginecol Obstet Mex* 78:486–492
96. Hou S (2013) Pregnancy in renal transplant recipients. *Adv Chronic Kidney Dis* 20:253–259
97. Josephson MA, McKay DB (2013) Women and transplantation: fertility, sexuality, pregnancy, contraception. *Adv Chronic Kidney Dis* 20:433–440
98. Richman K, Gohh R (2012) Pregnancy after renal transplantation: a review of registry and single-center practices and outcomes. *Nephrol Dial Transplant* 27:3428–3434